Could be but I don't think that's what it is. I think it has more to do with spending the money they have and where able to generate to achieve FDA approval. As far as manufacturing infrastructure, they've already said their ready to roll out saying their suppliers are ready to go. They better be ready to go if the buy-out theory doesn't hold water.
That makes perfect sense and is something I've mentioned before. I took it a step further in a prior post and suggested maybe their spending money, time and energy getting approvals around the Globe for a takeover. Of course the U.S. is going to be the holy grail and much effort has been spent over the past several years or so to make it happen. I have a strong suspension they are going to let this company go with or without an approval here in the U.S. ETRM is doing the dirty work and an acquiring company would be able to come in and manage it the way they want. This could also explain why there has been no partner or licensing agreements for where it has already been approved. The only question is who would be interested? All it takes is one look at the insiders at ETRM and one could see that Medtronics could be the front runner.
150,000 to 160,000 surgeries
I read that story yesterday. Pretty much said just what you said . Company/s in the obesity space have flopped but it's no longer time to be short and time to move on. Lets hope they move quickly tripping over themselves. Greedy pigs!!
Mark knudson: Restore Medical Incorporated was acquired by Medtronic, Inc.
Luke Evnin: Metabasis Therapeutics, Inc. (acquired by Ligand Pharmaceuticals, Inc.), Oscient Pharmaceuticals Corp. and Restore Medical, Inc. (acquired by Medtronic, Inc.)
Bobby Griffen: Retired from a 25 year career with Medtronic, Inc.
Mr. Tremmel: Medtronic, Inc he served in a variety of senior management positions, including President of the Neurological Division from 2003 to 2007, President of the Physio Control Division, President of the Tachyarrhythmia Management Division and President of the Interventional Vascular Division.
Your estimates are close to my lower end expectations. Maybe not what some are hoping for but probably closer to reality. I really doubt anyone buying at this level would have anything to worry about putting them comfortably ahead! Approval opens the doors to many possibilities.
I guess anything's possible, but I see more value than that with approval. My question is what will 12 days worth of volume look like on a thinly traded stock?
If you're waiting for EU approval you might want to rethink that. With the new updated guidelines added to weight control products I don't see any of the three companies getting approved anytime soon.
Updated on July 31 2014
The Draft Guidelines contain a new section on ruling out an increase in cardiovascular risk prior to submitting a marketing authorization application. Weight loss medicines should show a neutral or beneficial effect on parameters associated with cardiovascular risk. Any claim of a reduction of cardiovascular morbidity should be supported by clinical trials that enroll a representative sample of patients with obesity. At the time of submitting a marketing authorization application, the exclusion of an increase in cardiovascular risk of the study drug may be demonstrated by:
• at least 12 months of meta-analytical data, an analysis of medical literature and the absence of an increase in pre-clinical trials; or
• conducting a dedicated cardiovascular outcome study. The study population should mimic the target population and include a representative proportion of high-risk patients. The EMA recommends a composite endpoint of major cardiovascular events (MACE)
Looks like Jack was just playing nice. What he meant was "We welcome the competition,because we cannot wait until we bury them!" The competitions not so novel idea's and corrosive labels make it clear who the real winner is when it comes to pills in the obesity space! BELVIQ!!
And all those yelling dilution (guilty in the past) haven't taken into account that IF it where to happen shares would most certainly be eaten up by institutions. Maybe worth it to just do it and let them in. I'm hoping after realizing once again how they where wrong with OREX their will be a new influx of money here soon.
As Inns said we need approval first. But haven't you noticed that all the company/s in the space where priced for perfection resulting in sell the news events in EVERY case? In my opinion it is NOT that hard to see that ETRM is different in the fact it will have no where to run but up w/approval. There are nearly 8M shares shorted and 12 days worth of volume in shares that need to cover on approval. But beyond that there are many more opportunities to look forward too with an approval. After watching OREX just get approval with FORTY SEVEN pages attached to it I am pretty convinced i'm on the right side of the trade here!
Ticker symbol: EnteroMedics turn w/ FDA decision anytime and it's staring to run. Just as effective and safe with ZERO side affects.
Agree, and we unlike the other players in the field ARE NOT priced for approval. We will have room to RUN! I think people will notice this soon! How can they not!?
Liraglutide costs $3,214.10 per month it's a once a day injection. Five or six months of treatment which is probably not enough and you've already exceeded the cost of VBLOC.
Notes from panel:
Opposition vote came from Dr. David Kelsen of the Memorial Sloan Kettering Cancer Center, who said the research did not allay concerns about the potential for increased cancer risks. "Until that information is available, there is a risk of uncertainty," he said.
An FDA report released on Tuesday noted an imbalance in the number of breast malignancies among women who took the drug but said the available data neither supports nor denies the potential role of the drug in cancer promotion or progression.
The drug is also associated with higher resting heart rates and gallbladder-related problems.
The FDA and advisory panels continue to be on a roll approving anything obesity related. Our device is still the safest option and remember you quit taking these drugs and the weight comes back. One time deal for VBLOC and your done! Of course checkups would be needed but that's it.
5% to 8% although it looks like Arena may have got a boost by adding P in a 12 week study posted today. "WE AIN'T PILLS" should be our slogan!
Here's a thought. Why not VBLOC + P?
Not sure why Ade got 4 thumbs down. The fact is the FDA is approving everything related to obesity. Also a fact, VLBOC results are in line with FDA approved drugs with ZERO side affects. Investors have fallen alseep at the wheel on this one. Take a look at their market cap then look at Orex, Vivus, and Arena you'll see how ridiculously cheap it is. Being that it's a device and the advisory panel agreed we need something between pills and bariatric surgery also makes them a great takeout target too!